RhumbLine Advisers
OREX

RhumbLine Advisers’s Orexigen Therapeutics, Inc. OREX Stock Holding History

RhumbLine Advisers’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-11,544
Closed -$65K – 3127
2016
Q1 		$65K Buy
11,544
+178
+2% +$2.31K ﹤0.01% 2948
2015
Q4 		$195K Buy
11,366
+1,885
+20% +$44.9K ﹤0.01% 2810
2015
Q3 		$200K Sell
9,481
-97
-1% -$3.32K ﹤0.01% 2790
2015
Q2 		$474K Sell
9,578
-2,686
-22% -$161K ﹤0.01% 2371
2015
Q1 		$960K Buy
12,264
+2,073
+20% +$129K ﹤0.01% 1885
2014
Q4 		$618K Buy
10,191
+547
+6% +$27.5K ﹤0.01% 2145
2014
Q3 		$411K Sell
9,644
-395
-4% -$21.2K ﹤0.01% 2334
2014
Q2 		$620K Buy
10,039
+1,326
+15% +$77.1K ﹤0.01% 2135
2014
Q1 		$566K Buy
8,713
+4
+0% +$271 ﹤0.01% 2142
2013
Q4 		$490K Sell
8,709
-162
-2% -$9.1K ﹤0.01% 2271
2013
Q3 		$545K Buy
8,871
+155
+2% +$10.5K ﹤0.01% 2157
2013
Q2 		$510K Buy
+8,716
New +$536K ﹤0.01% 2238

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

RhumbLine Advisers's OREX Position: Q2 2016 in Review

RhumbLine Advisers sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2016, closing a stake of 11,544 shares — an estimated $65K sold.

RhumbLine Advisers first reported a position in OREX in Q2 2013 and held it in 12 quarters. The position peaked at $960K in Q1 2015. 73 funds tracked by Wall St. Rank hold OREX as of Q2 2016.

  • RhumbLine Advisers reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • RhumbLine Advisers sold 11,544 Orexigen Therapeutics, Inc. shares in Q2 2016, an estimated $65K.
  • RhumbLine Advisers first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 12 quarters.
  • RhumbLine Advisers's Orexigen Therapeutics, Inc. position peaked at $960K in Q1 2015.
  • 73 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2016.

Based on RhumbLine Advisers's 13F filing for Q2 2016, filed 11 Aug 2016.